A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273] by Collantes, Eduardo et al.
BioMed  Central
Page 1 of 10
(page number not for citation purposes)
BMC Family Practice
BMC Family Practice  2002,  3 x Research article
A multinational randomized, controlled, clinical trial of etoricoxib 
in the treatment of rheumatoid arthritis [ISRCTN25142273] 
Eduardo Collantes1, Sean P Curtis*2, Ka Wing Lee3, Noemi Casas4, 
Timothy McCarthy5, Agustin Melian2, Peng L Zhao2, Diana B Rodgers2, 
Calogera L McCormick2, Michael Lee2, Christopher R Lines2 and Barry 
JG e r t z 2 for the Etoricoxib Rheumatoid Arthritis Study Group
Address: 1Hospital Reina Sofia, Cordoba, Spain, 2Merck & Co., Inc., Rahway, NJ, USA, 3Pamela Youde Nethersole East Hospital, Hong Kong, 
4Clinica Reina Sofia, Bogata, Colombia and 5Manitoba Clinic, Winnipeg, Manitoba, Canada
E-mail: Eduardo Collantes - ecollantes@ctv.es; Sean P Curtis* - sean_curtis@merck.com; Ka Wing Lee - gavinlee@netvigator.com; 
Noemi Casas - ncasas@multi.net.co; Timothy McCarthy - timmccarthy@attglobal.net; Agustin Melian - agustin_melian@merck.com; Peng 
L Zhao - peng_zhao@merck.com; Diana B Rodgers - diana_rodgers@merck.com; Calogera L McCormick - calogera_mccormick@merck.com; 
Michael Lee - michael_lee@merck.com; Christopher R Lines - christopher_lines@merck.com; Barry J Gertz - barry_gertz@merck.com; 
the Etoricoxib Rheumatoid Arthritis Study Group - sean_curtis@merck.com
*Corresponding author
Abstract
Background: Etoricoxib is a highly selective COX-2 inhibitor which was evaluated for the treatment
of rheumatoid arthritis (RA).
Methods:  Double-blind, randomized, placebo and active comparator-controlled, 12-week study
conducted at 67 sites in 28 countries. Eligible patients were chronic NSAID users who demonstrated a
clinical worsening of arthritis upon withdrawal of prestudy NSAIDs. Patients received either placebo,
etoricoxib 90 mg once daily, or naproxen 500 mg twice daily (2:2:1 allocation ratio). Primary efficacy
measures included direct assessment of arthritis by counts of tender and swollen joints, and patient and
investigator global assessments of disease activity. Key secondary measures included the Stanford Health
Assessment Questionnaire, patient global assessment of pain, and the percentage of patients who
achieved ACR20 responder criteria response (a composite of pain, inflammation, function, and global
assessments). Tolerability was assessed by adverse events and routine laboratory evaluations.
Results: 1171 patients were screened, 891 patients were randomized (N = 357 for placebo, N = 353
for etoricoxib, and N = 181 for naproxen), and 687 completed 12 weeks of treatment (N = 242 for
placebo, N = 294 for etoricoxib, and N = 151 for naproxen). Compared with patients receiving placebo,
patients receiving etoricoxib and naproxen showed significant improvements in all efficacy endpoints
(p<0.05). Treatment responses were similar between the etoricoxib and naproxen groups for all
endpoints. The percentage of patients who achieved ACR20 responder criteria response was 41% in the
placebo group, 59% in the etoricoxib group, and 58% in the naproxen group. Etoricoxib and naproxen
were both generally well tolerated.
Conclusions: In this study, etoricoxib 90 mg once daily was more effective than placebo and similar in
efficacy to naproxen 500 mg twice daily for treating patients with RA over 12 weeks. Etoricoxib 90 mg
was generally well tolerated in RA patients.
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Background
Rheumatoid arthritis (RA) is a highly inflammatory,
chronic, systemic disease which affects connective tissue
and involves multiple joints. The traditional symptomatic
therapy for many inflammatory diseases, including RA,
has been nonsteroidal antiinflammatory agents (NSAIDs)
[1,2]. In RA, NSAIDs are often used in conjunction with
disease modifying antirheumatism drugs such as meth-
otrexate, or may be taken as monotherapy for symptomat-
ic relief [1,2]. While NSAIDs are effective in controlling
the joint pain and swelling in RA, their side effect profile
limits their use in some patients. In particular, the poten-
tial for gastrointestinal toxicity with traditional nonselec-
tive NSAIDs can be a significant limitation of their use [3].
Gastrointestinal bleeding, ulceration, and perforation, are
the most common serious adverse events associated with
NSAIDs and often lead to discontinuation of NSAID ther-
apy as well as expensive treatment for the gastropathic
symptoms themselves [4]. Continuous exposure to high
doses of NSAIDs, as well as frequent concomitant use of
steroids, puts RA patients at particular risk for gastrointes-
tinal-associated adverse events [3,5].
The new generation of NSAID treatments which selective-
ly inhibit cyclooxygenase-2 (COX-2) while sparing COX-
1 offer an alternative treatment option for many patients
with RA and other inflammatory disorders [6]. Previous
studies have shown that the selective COX-2 inhibitors,
rofecoxib and celecoxib, are effective and well-tolerated
treatments for RA, with decreased gastrointestinal toxicity
versus non-selective NSAIDs [6–8]. A recent clinical trial
conducted in the United States found that the new, highly
selective COX-2 inhibitor, etoricoxib (90 mg), was effec-
tive in the treatment of RA and also suggested that this
dose of etoricoxib might be more effective than a 1000-
mg dose of the non-selective NSAID naproxen [9]. The
present study conducted at sites throughout the world fur-
ther investigated the clinical profile of etoricoxib 90 mg in
RA patients.
Materials and Methods
General
This randomized, double-blind, parallel-group 12-week
study was conducted at 67 sites in 28 countries, including
the U.S. (see acknowledgments for list of countries and in-
vestigators). Patients were enrolled between November
1999 and June 2000. Each site received the approval of its
Ethics Review Committee or Institutional Review Board to
perform the study. Written informed consent was ob-
tained from every patient evaluated. Patients who discon-
tinued the study due to lack of efficacy or who completed
the 12-week, placebo-controlled trial were offered the op-
portunity to enter a blinded active comparator-controlled
40-week extension. The data from the 40-week, active
comparator-controlled extension will be reported sepa-
rately.
Patients
Eligible patients were age ≥ 18 years and fulfilled diagnos-
tic criteria for RA as specified by the 1987 revised criteria
of the American Rheumatism Association [10]. In addi-
tion, patients were required to have an established diag-
nosis of RA for at least 6 months prior to entering the
study, a history of a clinical response to NSAID therapy,
and to have been taking NSAID therapy on a regular basis
(at least 25 of the past 30 days). Patients with a history of
angina or congestive heart failure, with symptoms that oc-
curred at rest or minimal activity, and/or who had a histo-
ry of myocardial infarction, coronary angioplasty, or
coronary bypass within the past year were excluded as
were those with a history of stroke, transient ischemic at-
tack or hepatitis in the previous two years. Patients with
uncontrolled hypertension at screening were also exclud-
ed. Patients with any medical condition which, in the
opinion of the investigator, could have confounded study
results or caused undue risk to the patient (e.g., comorbid
conditions for which NSAIDs are contraindicated) were
also excluded. Three hemoccult screens were performed
prior to allocation and patients with any evidence of ac-
tive gastrointestinal bleeding were excluded. At randomi-
zation, patients could not be taking concomitant
warfarin, ticlopidine, clopidrogel or digoxin. Patients on
stable doses of disease modifying therapy (except TNF in-
hibitors) and low doses of corticosteroids (prednisone
<10 mg daily) were allowed to continue therapy. Patients
were permitted to take low dose aspirin (up to 100 mg/
day), but in practice <3% patients used aspirin during the
study.
Procedure
Patients were assessed for disease activity and those who
met entry criteria were asked to discontinue their current
NSAID use and return for evaluation when symptoms
worsened (disease flare). At re-evaluation for study inclu-
sion, patients were required to have ≥  6 tender joints, ≥  3
swollen joints, and at least a 20% increase in the number
of tender and swollen joints compared with screening vis-
it assessments. In addition, investigators must have rated
patients as "fair," "poor," or "very poor" on the investiga-
tor global assessment of disease activity, and noted either
of the following: 1) morning stiffness for ≥ 45 minutes
plus increased duration of morning stiffness by at least 15
minutes since screening visit evaluation, or 2) a score of
>40 mm on patient global assessment of pain (a 100-mm
visual analog scale [VAS]) and at least a 10-mm increase
in patient assessment of pain over that reported at screen-
ing visit evaluation.BMC Family Practice 2002, 3 http://www.biomedcentral.com/1471-2296/3/10
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Patients meeting the above flare criteria were randomized
to placebo, etoricoxib 90 mg once daily, or naproxen 500
mg twice daily in a 2:2:1 allocation ratio. Randomization
was stratified by use or non-use of low-dose corticoster-
oids. Efficacy evaluations were performed at baseline and
at weeks 2, 4, 8, and 12. Efficacy assessments included all
components of the American College of Rheumatology
(ACR) core set of outcome measures: tender joint count,
swollen joint count, patient global assessment of disease
activity, investigator global assessment of disease activity,
Stanford Health Assessment Questionnaire (HAQ) of dis-
ability (an assessment of the patient's mobility and ability
to carry out activities of daily living), patient global assess-
ment of pain, and C-reactive protein level [2,10]. Four
endpoints were specified as primary: tender joint count
(total 68 joints), and swollen joint count (total 66 joints),
patient global assessment of disease activity (100-mm
VAS; 0 = "very well", 100 = "very poor"), investigator glo-
bal assessment of disease activity (0 to 4 Likert scale; 0 =
"very well", 1 = "well", 2 = "fair", 3 = "poor", 4 = "very
poor"). Key secondary measures included patient global
assessment of pain (100-mm VAS; 0 = "no pain", 100 =
"extreme pain"), HAQ disability score (the average score
of 9 disability questions, each graded on a 0 to 3 Likert
scale: 0 = "without any difficulty", 1 = "with some difficul-
ty", 2 = "with much difficulty", 3 = "unable to do"), and
the proportion of patients who met the ACR20 criteria for
a clinically relevant response (a composite criteria requir-
ing 20% improvement in tender and swollen joint counts
and 20% improvement in 3 of the 5 remaining ACR core
measures) [10] and who completed the study (ACR20-
completers). The percentage of patients who discontinued
due to lack of efficacy were also measured. For complete-
ness, we also looked at the percentage of patients meeting
ACR20 criteria regardless of whether or not they complet-
ed the study.
Laboratory assessments (serum chemistry, complete
blood count, urinalysis) were performed at baseline and
at weeks 2, 4, 8 and 12. Clinical and laboratory adverse
events were recorded throughout the study. Investigators
rated the intensity, relation to study drug (possibly, prob-
ably, or definitely drug-related; probably not or definitely
not drug-related), and seriousness (includes events which
are life threatening, result in hospitalization, or cause per-
manent incapacity, or other significant event) of adverse
events. All potential upper gastrointestinal perforations,
ulcers and bleeds (PUBs) and all potential cardiovascular
thrombotic events (including cardiac, peripheral vascular
and cerebrovascular events) were reviewed by independ-
ent blinded adjudication committees, who determined if
they were confirmed events according to pre-specified
case definitions (confirmed adjudicated events) [6].
Statistical analysis
The primary analytic method for evaluating efficacy was
to compare treatment groups using the time-weighted av-
erage change from baseline across 12 weeks for the 7 ACR
core measures. The rates at 12 weeks for ACR20-compl-
eters, and the cumulative rates over 12 weeks for discon-
t i n u a t i o n s  d u e  t o  l a c k  o f  e f f i c a c y  w e r e  a l s o  c o m p a r e d
between treatment groups. Pair-wise comparisons were
based on the difference between mean responses, except
for C-reactive protein level, where the mean ratio was an-
alyzed via log transformation. A modified intent-to-treat
approach was employed – all patients with baseline and
at least 1 post-baseline measurement were included in the
analysis. Analysis of covariance (including terms for base-
line covariate, stratum [corticosteroid use], and treat-
ment) was used for all efficacy variables except ACR20-
completers, and discontinuation rates due to lack of effi-
cacy. The percentages of patients meeting ACR20-compl-
eters criteria were compared between treatment groups
using the Cochran-Mantel-Haenszel test with corticoster-
oid use as a stratification factor, and Fisher's Exact test was
used to make between-treatment comparisons of the dis-
continuation rates due to lack of efficacy. The analysis of
serum C-reactive protein was based on the log of on-treat-
ment value over baseline value. Plots of mean changes
from baseline at each time point for the 4 primary end-
points were made to assess the maintenance of therapeu-
tic effect for etoricoxib and naproxen. A last-observation-
carried-forward method was used for these longitudinal
graphs, but not for the time-weighted average changes
shown in the table of results.
Tolerability was evaluated by tabulation of all clinical and
laboratory safety parameters, including adverse events.
Active treatments were compared with placebo using Fish-
er's exact test for the percentages of patients with any drug-
related clinical adverse event, with any serious clinical ad-
verse event, or who discontinued due to a clinical adverse
event. Evaluations of data regarding safety were made by
various means, including an examination of patients ex-
ceeding predefined limits for laboratory values of interest
(e.g., consecutive decreases in hemoglobin and hemat-
ocrit, increased aminotransferase values, or increases in
serum creatinine), common events associated with
NSAIDs or COX-2 inhibitors (e.g., hypertension and low-
er extremity edema), and percentages of patients discon-
tinuing due to adverse events.
Results
Patients
Of the 1171 patients screened, 891 met eligibility criteria
and were randomized. Baseline characteristics of the 891
patients in the 3 treatment groups were similar and are
shown in Table 1. A total of 687 of the 891 patients
(67.8% of the placebo group, 83.3% of the etoricoxibBMC Family Practice 2002, 3 http://www.biomedcentral.com/1471-2296/3/10
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group, and 83.4% of the naproxen group) completed the
12-week study (Figure 1). The mean number of days pa-
tients were on treatment was 65.5 for placebo, 76.0 for
etoricoxib, and 76.5 for naproxen. The most common rea-
son for discontinuation was lack of efficacy, and signifi-
cantly more patients discontinued due to lack of efficacy
in the placebo group than in the etoricoxib and naproxen
group (25.2%, 12.5%, 10.5%, respectively, p<0.001 vs
placebo). The results of all patients who had at least one
post-randomization efficacy measurement were included
in the primary analysis of efficacy (93.0% in the placebo
group, 97.5% in the etoricoxib group and 96.1% in the
naproxen group).
Efficacy
Table 2 summarizes the results of the treatment compari-
sons for the primary and secondary efficacy endpoints.
For all 4 primary endpoints, etoricoxib and naproxen
were statistically superior to placebo. For all secondary
endpoints, except serum C-reactive protein, both etoricox-
ib and naproxen were also superior to placebo. Serum C-
reactive protein levels increased on etoricoxib compared
to placebo. This was not seen in the naproxen group.
There was no significant difference between etoricoxib
and naproxen for any of the primary or secondary end-
points. The percentage of patients who achieved ACR20
responder criteria response was 40.9% in the placebo
group, 58.7% in the etoricoxib group, and 57.5% in the
naproxen group. Treatment effects of etoricoxib were rap-
id, occurring at the earliest time point measured (week 2),
and were maintained over the entire 12-week study period
(Figures 2a,2b,2c,2d). Treatment effects of etoricoxib were
consistent across corticosteroid users and non-users.
Tolerability
The adverse event rates for the 3 treatment groups are
summarized in Table 3. Clinical adverse events deter-
mined by the investigator as possibly, probably, or defi-
nitely drug-related occurred in 15.4%, 23.2%, and 19.3%
of patients in the placebo, etoricoxib 90 mg, and naprox-
en 500 mg twice daily groups (p<0.05 for etoricoxib ver-
sus placebo). There was no individual drug-related
adverse event that was predominantly responsible for the
difference between etoricoxib and placebo; in fact, there
were no individual drug-related adverse events with an in-
cidence  ≥ 4% in any treatment group. The active treat-
ments were not significantly different from placebo
(p>0.05) with regard to the percentages of patients with
any serious clinical adverse event or who discontinued
due to a clinical adverse event (Table 3). Only 3 of the se-
rious clinical adverse events were judged to be drug-relat-
ed by the investigators: 2 on etoricoxib (duodenal ulcer
and hip pain) and 1 on naproxen (hypertension). There
were no deaths reported. No clinically relevant trends
were noted in the overall incidence of laboratory adverse
events or mean changes in alanine aminotransferase, as-
partate aminotransferase, serum creatinine, and hemo-
globin plus hematocrit.
Table 1: Baseline patient characteristics
Characteristic Placebo Etoricoxib 90 mg Naproxen 1000 mg
(N = 357) (N = 353) (N = 181)
% women 82 81 82
Mean age [yrs] (SD) 52 (12) 53 (12) 52 (12)
Mean duration of rheumatoid arthritis [yrs] (SD) 9 (8) 8 (8) 8 (8)
% rheumatoid factor-positive 83 85 87
% in ARA functional class:
I2 7 3 1 2 7
II 56 53 58
III 17 16 16
% taking rheumatoid arthritis medications:
Corticosteroids 57 54 59
Disease modifying antirheumatic drugs 83 83 81
Methotrexate 59 55 62
Mean patient global assessment of disease activity (100 
mm visual analog scale) ‡ (SD)
65 (19) 66 (20) 65 (19)
Mean investigator global assessment of disease activity 
(0 to 4 scale) ‡ (SD)
2.7 (0.6) 2.7 (0.7) 2.7 (0.6)
Mean number of tender joints (of 68) ‡ (SD) 29 (15) 29 (15) 28 (15)
Mean number of swollen joints (of 66) ‡ (SD) 19 (12) 19 (13) 18 (12)
‡ Higher score corresponds to greater disease activity.BMC Family Practice 2002, 3 http://www.biomedcentral.com/1471-2296/3/10
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Figure 1
Study flowchart. AE = adverse event. "Discontinued due to other reasons" = patient lost to follow-up, moved, withdrew con-
sent, protocol deviation, study site terminated.
891 Patients Randomized to Enter Study
357 Randomized to 
Placebo
353 Randomized to 
Etoricoxib 90 mg
181 Randomized to 
Naproxen 1000 mg
90 (25.2%) 
Discontinued due to 
Lack of Efficacy
44 (12.5%) 
Discontinued due to 
Lack of Efficacy
19 (10.5%) 
Discontinued due to 
Lack of Efficacy
6 (1.7%) 
Discontinued due to 
Clinical AE
8 (2.3%) 
Discontinued due to 
Clinical AE
4 (2.2%) 
Discontinued due to 
Clinical AE
4 (1.1%) 
Discontinued due to 
Laboratory AE
0 (0.0%) 
Discontinued due to 
Laboratory AE
0 (0.0%) 
Discontinued due to 
Laboratory AE
15 (4.2%) 
Discontinued due to 
Other Reasons
 7 (2.0%) 
Discontinued due to 
Other Reasons
7 (3.9%) 
Discontinued due to 
Other Reasons
242 (67.8%) 
Completed Part I
(12 weeks) of the Trial
294 (83.3%) 
Completed Part I
(12 weeks) of the Trial
151 (83.4%) 
Completed Part I 
(12 weeks) of the Trial
1171 Patients ScreenedBMC Family Practice 2002, 3 http://www.biomedcentral.com/1471-2296/3/10
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The most commonly reported adverse events, those with
an incidence of ≥ 3% in any treatment group, are summa-
rized in Table 4. Events of special interest in evaluating
COX inhibitors are also summarized in Table 4. The inci-
dence of gastrointestinal nuisance symptoms was similar
among all treatment groups (10.1%, 10.8%, and 11.6% in
the placebo, etoricoxib and naproxen groups, respective-
ly). The incidence of lower extremity edema adverse
events in the study was low and similar among treatment
groups. No patients discontinued due to lower extremity
edema. Although there was an increase in hypertension
adverse events in patients taking etoricoxib and naproxen
versus placebo, discontinuations due to hypertension ad-
verse events were rare (1 patient on naproxen). Over 12
weeks, mean systolic blood pressures decreased slightly
from baseline in the placebo group, and increased slightly
in the etoricoxib and naproxen groups (the maximum dif-
ference between means at any time point was <3.5 mm Hg
for etoricoxib and <2 mm Hg for naproxen) (Figure 3).
Mean diastolic blood pressures did not change substan-
tially from baseline values in any treatment group during
the study (the maximum difference at any time point was
≤ 1.1 mm Hg). There was only 1 confirmed duodenal ulcer
in the study (in the etoricoxib treatment group). There
were 3 confirmed cardiovascular thrombotic adverse
Figure 2
Changes from baseline on primary endpoints: a) tender joint counts; b) swollen joint counts; c) patient global assessments of
disease activity; d) investigator global assessments of disease activity. S = screening visit, R = randomization (baseline) visit; SE =
standard error. Screening (S) to randomization (R) = washout period for prior NSAID therapy. Empty circle = placebo, empty
triangle = etoricoxib 90 mg, solid diamond = naproxen 1000 mg. A last-observation-carried-forward approach was used for
missing values.
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events: 2 on etoricoxib (angina pectoris and pulmonary
embolism) and 1 on placebo (thrombophlebitis).
Discussion
This multinational study confirmed findings from a repli-
cate study [9] that a 90-mg daily dose of the COX-2 selec-
tive inhibitor, etoricoxib, was more effective than placebo
for treating patients with RA. The treatment effects of etor-
icoxib occurred by the first assessment (at 2 weeks) and
were sustained throughout the 12 weeks of the study.
Etoricoxib showed similar efficacy to a high dose of the
non-selective NSAID naproxen, supporting results from
studies with other selective COX-2 inhibitors in RA which
also showed similar efficacy to non-selective NSAIDs
[7,8]. The results differed from those in the replicate study
of etoricoxib in RA [9] which found that etoricoxib was
more effective than naproxen. The reason for the differ-
ence in results between the two studies is unclear since the
studies had identical designs, including entry criteria, dos-
es of study medication, and outcome measures. However,
although patient enrollment criteria were identical, more
patients in the present study were using concomitant cor-
ticosteroids (approximately 57% versus 32%) and disease
modifying antirheumatic drugs, including methotrexate
(approximately 82% versus 68%). It is conceivable that
the increased concomitant RA medication use may have
obscured the ability to detect small, but perhaps meaning-
ful differences between active treatments. Interestingly, in
this study as compared to the replicate etoricoxib RA study
[9], the placebo response rate was higher (ACR20-re-
sponders were 40.9% in the current study versus 20.8% in
the replicate study) and the discontinuations due to lack
of efficacy were lower in the placebo group (25.2% in the
current study vs 54.5% in the replicate study), and this
may also have influenced the results. Although unproven,
other potential explanations may relate to the fact that the
present study was conducted largely outside the United
States and the previous study inside the United States [9].
Therefore, differences in underlying disease characteristics
and/or cultural differences in perceptions of efficacy may
have also contributed to the difference in the results. Oth-
ers have reported different findings for RA studies with
similar designs which were conducted in the United States
versus other countries. Serum C-reactive protein levels
were noted to be elevated compared to placebo in the
etoricoxib group. This was not observed in other etoricox-
ib RA studies [19,9]; in one study no difference was seen
from placebo [19], and in the other study a lowering in se-
rum C-reactive protein was observed [9]. It is generally not
believed that changes in serum C-reactive protein are sub-
stantially influenced by NSAID treatment. Therefore, this
was not felt to represent a clinically meaningful finding.
Etoricoxib was generally well tolerated by the patients in
this study, consistent with results from prior clinical trials
of etoricoxib for RA and other indications [9,11–13].
There was a significantly higher number of patients with
drug-related clinical adverse events for etoricoxib versus
placebo. However, the difference was small and should be
interpreted with caution since more patients on placebo
discontinued early (primarily due to lack of efficacy) and
therefore had less chance of experiencing an adverse
event. The findings may therefore overestimate adverse
event rates for the active treatments compared with place-
bo.
Particular attention was paid to the typical NSAID-related
renal effects of edema and hypertension since data with
both selective COX-2 inhibitors and non-selective
NSAIDs have suggested that they have an effect on renal
physiology [14,15]. Etoricoxib and naproxen showed a
small increase in hypertension adverse events compared
with placebo. Mean changes in blood pressure among the
treatment groups was small, and both etoricoxib and
naproxen treatment groups showed only small increases
in mean systolic blood pressure compared to baseline.
Among patients who had hypertension adverse events on
etoricoxib, no patient discontinued from the study. The
incidences of lower extremity edema adverse events for
etoricoxib were similar to placebo and no patient treated
with etoricoxib discontinued as a result.
The main proposed advantage for selective COX-2 inhibi-
tors is reduced gastrointestinal toxicity. However, a thor-
Figure 3
Mean changes from baseline in systolic blood pressure (mm
Hg). S = screening visit, R = randomization (baseline) visit; SE
= standard error. Screening (S) to randomization (R) = wash-
out period for prior NSAID therapy. Empty circle = placebo,
empty triangle = etoricoxib 90 mg, solid diamond =
naproxen 1000 mg.
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ough and adequate assessment of this can only be made
either in very large long-term trials or pooled analyses be-
cause of the relatively low incidence of clinically signifi-
cant gastrointestinal PUBs [6,16]. In fact, only one
confirmed PUB was reported in the present study.
It has also been suggested [6,17,18] that the use of selec-
tive COX-2 agents may be associated with a higher inci-
dence of cardiovascular thrombotic events than naproxen
(a potent and sustained inhibitor of platelet aggregation
at therapeutic doses). As with upper GI clinical events
(PUBs), these events are rare and conclusive data can only
be adequately amassed in large data sets. The incidence of
confirmed cardiovascular thrombotic events in the
present study was low (3 events), therefore no meaningful
conclusions about the overall cardiovascular safety of
etoricoxib can be determined from this single study.
Conclusions
In summary, etoricoxib 90 mg once daily provided clini-
cally meaningful improvements of the signs and symp-
toms of RA that were superior to those of placebo and
comparable to those of naproxen 500 mg twice daily.
Etoricoxib 90 mg was generally well tolerated in this
study. These data provide further support for the addition
of etoricoxib to the available therapeutic options in the
management of RA patients.
Table 2: Mean (95% confidence interval) efficacy differences between treatments over 12 weeks
Etoricoxib vs placebo Naproxen vs placebo Etoricoxib vs naproxen
Primary endpoints
Patient global assessment of disease activity (100 mmVAS) ‡ -9.93* (-12.96, -6.90) -10.0* (-13.7, -6.32) 0.09 (-3.61, 3.79)
Investigator global assessment of disease activity (0–4 scale) ‡ -0.43* (-0.55, -0.30) -0.51* (-0.66, -0.35) 0.08 (-0.08, 0.24)
Tender joint count (total 68 joints) ‡ -3.42* (-4.89, -1.94) -3.16* (-4.96, -1.36) -0.26 (-2.05, 1.54)
Swollen joint count (total 66 joints) ‡ -1.43† (-2.42, -0.44) -1.39† (-2.60, -0.19) -0.03 (-1.24, 1.17)
Secondary endpoints
Patient global assessment of pain (100 mm VAS) ‡ -9.62* (-12.73, -6.51) -10.46* (-14.25, -6.66) 0.84 (-2.96, 4.63)
Health Assessment Questionnaire disability (0–3 scale) ‡ -0.20* (-0.28, -0.13) -0.29* (-0.38, -0.20) 0.08 (0.00, 0.17)
Serum C-reactive protein (ratio between treatments) 1.11† (1.00, 1.23) 0.99 (0.87, 1.13) 1.12 (0.99, 1.27)
ACR20 responder criteria (%) 17.83* (10.55, 25.12) 16.68* (7.80, 25.57) 1.15 (-7.74, 10.03)
Discontinuation due to lack of efficacy (%) -12.75* (-18.42, -7.07) -14.71* (-21.06, -8.37) 1.97 (-3.67, 7.61)
Note: Negative values indicate improvement except for ACR20 responder criteria and serum C-reactive protein.
* The difference vs placebo was significant (p<0.001). 
† The difference vs placebo was significant (p<0.05). 
‡ For these measures, the difference shown is for the least squares mean of the time-weighted average change from baseline over 12 weeks. ACR20 
responder criteria and Discontinuations due to lack of efficacy are shown as differences in frequency over the 12-week period. Serum C-reactive 
protein was calculated as a ratio between treatments over the 12-week treatment period.
Table 3: Summary of safety data
Placebo Etoricoxib 90 mg Naproxen 1000 mg
(N = 357) (N = 353) (N = 181)
n (%) n (%) n (%)
Number of patients:
With any drug-related clinical adverse event 55 (15.4) 82 (23.2) † 35 (19.3)
With any serious clinical adverse event‡ 3 (0.8) 7 (2.0) 3 (1.7)
Discontinued due to clinical adverse event 6 (1.7) 9 (2.5) 5 (2.8)
† p < 0.05 vs placebo.
‡ Serious adverse events were: placebo (3 patients) – thrombophlebitis, atrial fibrillation, and pneumothorax; etoricoxib (7 patients) – pulmonary 
embolism, angina pectoris, thyroid cancer, duodenal ulcer, hip pain, femoral fracture, and traumatic arthropathy plus corneal degeneration (in the 
same patient); naproxen (3 patients) – hypertension, intervertebral disc displacement, and retinal detachment.BMC Family Practice 2002, 3 http://www.biomedcentral.com/1471-2296/3/10
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